Analyst opinion on the stock is divided. Among the skeptics, CFRA assigned the stock a sell rating on Friday, setting a 12-month target of $115 — implying a roughly 29% retreat from where shares finished that day — with analysts at the firm pointing to the company's aggressive expansion ambitions, lofty valuation, and heavy capital demands as key concerns. A June 8 research note from Morningstar put fair value at $63 a share, with analyst Nicolas Owens characterizing the stock as overvalued at current prices. NewStreet Research, by contrast, initiated coverage with a $165 price target.